ETFs Lupin Limited

500257

INE326A01037

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 11:00:56 05/06/2026 BST			5-day change	1st Jan Change
2,268.10 ^INR	+0.86%		-0.19%	+7.39%

06-05	Lupin Gets US FDA Approval for Ranluspec Interchangeable Biosimilar for Eyesight Ailments	MT
06-04	Lupin Limited Receives Approval from U.S. FDA for Ranluspec Ranibizumab Injection	CI

ETFs positioned on Lupin Limited

Name	Varia. Jan 1.	Weight	AuM
VANGUARD INTERNATIONAL EQUITY INDEX FUNDS - VANGUARD FTSE ALL-WORLD EX-US ETF	+6.34%	0.01%	33,076 M€
VANGUARD LIFESTRATEGY 40% EQUITY UCITS ETF - DISTRIBUTING - EUR	+4.37%	0%	37 M€
VANGUARD LIFESTRATEGY 20% EQUITY UCITS ETF - DISTRIBUTING - EUR	+1.70%	0%	15 M€

Lupin Limited is a leading Indian pharmaceutical group. Its products are used to treat tuberculosis, diabetes, asthma, cardiovascular diseases, infections, etc. The group's activity is organized around 2 areas: - design and production of generic and brand-name formulations; - production of active pharmaceutical ingredients. At the end of March 2022, the group had 15 production sites India (12), the United States, Mexico and Brazil. Net sales break down geographically as follows: India (39.4%), the United States (34.1%) and other (26.5%).

Employees

24,006

Sector

Pharmaceuticals

More about the company